These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 8335014)

  • 21. Immunogenicity of a five-component acellular pertussis vaccine in infants and young children.
    Halperin SA; Barreto L; Friesen B; Meekison W
    Arch Pediatr Adolesc Med; 1994 May; 148(5):495-502. PubMed ID: 7910089
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children.
    Pichichero ME; Deloria MA; Rennels MB; Anderson EL; Edwards KM; Decker MD; Englund JA; Steinhoff MC; Deforest A; Meade BD
    Pediatrics; 1997 Nov; 100(5):772-88. PubMed ID: 9346976
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diphtheria, tetanus and pertussis antibodies in 10-year-old children before and after a booster dose of three toxoids: implications for the timing of a booster dose.
    Trollfors B; Knutsson N; Taranger J; Mark A; Bergfors E; Sundh V; Lagergård T
    Eur J Pediatr; 2006 Jan; 165(1):14-8. PubMed ID: 16249929
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dose-response to a two-component acellular pertussis vaccine in infants and comparison with whole-cell vaccine.
    Auerbach BS; Lake AM; Wilson ME; Willingham FF; Shematek J; Moulton L; Deforest A; Halsey NA
    Biologicals; 1998 Jun; 26(2):145-53. PubMed ID: 9811522
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acellular vaccines induce cell-mediated immunity to Bordetella pertussis antigens in infants undergoing primary vaccination against pertussis.
    Ausiello CM; Urbani F; La Sala A; Lande R; Piscitelli A; Cassone A
    Dev Biol Stand; 1997; 89():315-20. PubMed ID: 9272365
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A new DTPw-HBV/Hib vaccine: immune memory after primary vaccination and booster dosing in the second year of life.
    Gatchalian S; Reyes M; Bermal N; Chandrasekaran V; Han HH; Bock HL; Lefevre I
    Hum Vaccin; 2008; 4(1):60-6. PubMed ID: 18376148
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overview of the clinical development of a diphtheria-tetanus--acellular pertussis vaccine.
    Bogaerts H; Capiau C; Hauser P; Mareschal JC; Mélot V; Simons D
    J Infect Dis; 1996 Nov; 174 Suppl 3():S276-80. PubMed ID: 8896529
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK.
    Marlow R; Kuriyakose S; Mesaros N; Han HH; Tomlinson R; Faust SN; Snape MD; Pollard AJ; Finn A
    Vaccine; 2018 Apr; 36(17):2300-2306. PubMed ID: 29576304
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessment of the immunogenicity and reactogenicity of a quadrivalent diphtheria, tetanus, acellular pertussis and hepatitis B (DTPa-HBV) vaccine administered in a single injection with Haemophilus influenzae type b conjugate vaccine, to infants at 2, 4 and 6 months of age.
    Arístegui J; Dal-Ré R; Garrote E; González A; Arrate JP; Pérez A
    Vaccine; 1998 Dec; 16(20):1976-81. PubMed ID: 9796053
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and immunogenicity of acellular pertussis vaccine combined with diphtheria and tetanus toxoids in 17- to 24-month-old children.
    Glode M; Joffe L; Reisinger K; Blatter M; Plotkin S; Watson B; Grossman L; Asmar B; Berry M; Starobin S
    Pediatr Infect Dis J; 1992 Jul; 11(7):530-5. PubMed ID: 1528643
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience.
    Salmaso S; Mastrantonio P; Tozzi AE; Stefanelli P; Anemona A; Ciofi degli Atti ML; Giammanco A;
    Pediatrics; 2001 Nov; 108(5):E81. PubMed ID: 11694665
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Local reactions and IgE antibodies to pertussis toxin after acellular diphtheria-tetanus-pertussis immunization.
    Edelman K; Malmström K; He Q; Savolainen J; Terho EO; Mertsola J
    Eur J Pediatr; 1999 Dec; 158(12):989-94. PubMed ID: 10592076
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical reactions and immunogenicity of the BIKEN acellular diphtheria and tetanus toxoids and pertussis vaccine in 4- through 6-year-old US children.
    Bernstein HH; Rothstein EP; Pichichero ME; Francis AB; Kovel AJ; Disney FA; Green JL; Marsocci SM; Lynd AM; Wood GC
    Am J Dis Child; 1992 May; 146(5):556-9. PubMed ID: 1621656
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diphtheria-tetanus-acellular pertussis vaccine adsorbed (Triacelluvax; DTaP3-CB): a review of its use in the prevention of Bordetella pertussis infection.
    Matheson AJ; Goa KL
    Paediatr Drugs; 2000; 2(2):139-59. PubMed ID: 10937466
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of acellular and whole-cell pertussis-component DTP vaccines. A multicenter double-blind study in 4- to 6-year-old children.
    Morgan CM; Blumberg DA; Cherry JD; Reisinger KS; Blatter MM; Blumer JL; Dekker CL; Stout MG; Christenson PD
    Am J Dis Child; 1990 Jan; 144(1):41-5. PubMed ID: 2403747
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children.
    Pichichero ME; Edwards KM; Anderson EL; Rennels MB; Englund JA; Yerg DE; Blackwelder WC; Jansen DL; Meade BD
    Pediatrics; 2000 Jan; 105(1):e11. PubMed ID: 10617748
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and immunogenicity of two formulations of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae conjugate-hepatitis B vaccine in 15 to 18-month-old children.
    Halperin SA; Langley JM; Hesley TM; Zappacosta PS; Radley D; Smith B; Hoffenbach A; Boslego J; Silber JL
    Hum Vaccin; 2005; 1(6):245-50. PubMed ID: 17012871
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of safety and efficacy against Bordetella pertussis of a new tetanus-reduced dose diphtheria-acellular pertussis vaccine in a murine model.
    Kwon HJ; Han SB; Kim BR; Kang KR; Huh DH; Choi GS; Ahn DH; Kang JH
    BMC Infect Dis; 2017 Apr; 17(1):247. PubMed ID: 28376777
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acellular and whole-cell pertussis vaccines as booster doses: a multicenter study.
    Englund JA; Decker MD; Edwards KM; Pichichero ME; Steinhoff MC; Anderson EL
    Pediatrics; 1994 Jan; 93(1):37-43. PubMed ID: 8265321
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized trial of two acellular pertussis vaccines (dTpa and pa) and a licensed diphtheria-tetanus vaccine (Td) in adults.
    Turnbull FM; Heath TC; Jalaludin BB; Burgess MA; Ramalho AC
    Vaccine; 2000 Nov; 19(6):628-36. PubMed ID: 11090714
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.